Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib with oxaliplatin and capecitabine in HER2-positive resectable oesophageal and gastric adenocarcinoma
ISRCTN49623344Phase 4Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jun 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of lapatinib, oxaliplatin and capecitabine in gastric adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Molecular response. Started Jun 2011; status: completed.
02
Drugs
lapatiniboxaliplatincapecitabine
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on ISRCTN49623344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN49623344.